{
    "id": 1392,
    "fullName": "ALK R1192P",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK R1192P lies within the protein kinase domain of the Alk protein (UniProt.org). R1192P confers a gain of function to the Alk protein as demonstrated by transformed cells and increased downstream signalling, although less robustly than other activating mutants (PMID: 21838707).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 527,
                    "pubMedId": 21838707,
                    "title": "Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21838707"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "R1192P",
    "createDate": "08/12/2014",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102080,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220776C>G",
        "cDna": "c.3575G>C",
        "protein": "p.R1192P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).",
            "molecularProfile": {
                "id": 1415,
                "profileName": "ALK R1192P"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5182,
                    "pubMedId": 27049722,
                    "title": "Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5362,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells overexpressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20660,
                "profileName": "EML4 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5361,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20660,
                "profileName": "EML4 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5364,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20660,
                "profileName": "EML4 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5365,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20660,
                "profileName": "EML4 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5360,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20660,
                "profileName": "EML4 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5363,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20660,
                "profileName": "EML4 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5354,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5350,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5357,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5356,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5355,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5358,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5359,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture compared to cells expressing wild-type NPM1-ALK (PMID: 27009859).",
            "molecularProfile": {
                "id": 20661,
                "profileName": "NPM1 - ALK ALK R1192P"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5026,
                    "pubMedId": 27009859,
                    "title": "TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009859"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1415,
            "profileName": "ALK R1192P",
            "profileTreatmentApproaches": [
                {
                    "id": 49,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK R1192P"
                }
            ]
        },
        {
            "id": 20660,
            "profileName": "EML4 - ALK ALK R1192P",
            "profileTreatmentApproaches": [
                {
                    "id": 16821,
                    "name": "Brigatinib",
                    "profileName": "EML4 - ALK ALK R1192P"
                },
                {
                    "id": 16823,
                    "name": "Crizotinib",
                    "profileName": "EML4 - ALK ALK R1192P"
                },
                {
                    "id": 16820,
                    "name": "AZD3463",
                    "profileName": "EML4 - ALK ALK R1192P"
                },
                {
                    "id": 16822,
                    "name": "Alectinib",
                    "profileName": "EML4 - ALK ALK R1192P"
                }
            ]
        },
        {
            "id": 20661,
            "profileName": "NPM1 - ALK ALK R1192P",
            "profileTreatmentApproaches": [
                {
                    "id": 16867,
                    "name": "Brigatinib",
                    "profileName": "NPM1 - ALK ALK R1192P"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102080,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220776C>G",
            "cDna": "c.3575G>C",
            "protein": "p.R1192P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}